Genoks and healthcare technology company Velsera have partnered to enhance diagnostics and treatment for cancer in Turkey and surrounding regions.
The collaboration will integrate Velsera’s Clinical Genomics Workspace (CGW) with Genoks’s knowledge in genomics to improve the detection and characterisation of various cancer types.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The CGW platform from Velsera is designed for comprehensive analysis of data from solid tissue, liquid tumours, and haematological cancer samples.
It is tailored for oncology and inherited disease specialists, facilitating the growth of next-generation sequencing (NGS) testing programmes.
Genoks plans to leverage Velsera’s capabilities in data interpretation and genomic analysis to enhance its oncology diagnostics capabilities in Turkey.
By adopting Velsera’s advanced algorithms and tools, Genoks aims to provide precise and personalised testing solutions. This will enable healthcare providers to offer targeted treatments based on each patient’s genetic profile.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe partnership is expected to advance Genoks’ position in oncology diagnostics in the country.
The collaboration between Genoks and Velsera highlights the importance of strategic partnerships in driving forward cancer research and improving patient outcomes.
Genoks clinical geneticist Dr Yunus Alp said: “We are thrilled to partner with Velsera in our shared mission to revolutionise cancer diagnostics and treatment in Turkey and beyond.
“Together, we are poised to make a significant impact in the fight against cancer, empowering clinicians with precise insights to guide treatment decisions and improve patient outcomes.”
